NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. The progressive damage to the liver associated with NASH resembles the pathology associated with excessive alcohol consumption or viral infections. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. This might drive the stock higher in the near term. This holistic approach offers the potential to address the complex, multi-organ/tissue pathogenesis of NASH, including improvements in risk factors linked to cardiovascular disease – the leading cause of death in NASH patients. Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's … This might drive the stock higher in the near term. Akero Therapeutics, Inc. (AKRO) Upgraded to Buy: Here's Why. Efruxifermin was designed to increase insulin sensitivity, improve lipoproteins, reduce liver fat and inflammation, and reverse fibrosis. See the company profile for Akero Therapeutics, Inc. (AKRO), including business summary, industry/sector information, number of employees, corporate governance, key … Akero Therapeutics, Inc. (AKRO) Upgraded to Buy: Here's Why. Currency in USD Get the latest Akero Therapeutics, Inc. (AKRO) stock news and headlines to help you in your trading and investment decisions.
ttm. Discover historical prices for AKRO stock on Yahoo Finance.
As a result, NASH has become a leading cause of liver transplants in the US and Efruxifermin (EFX), formerly AKR-001, is Akero's lead product candidate for NASH. Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. This might drive the stock higher in the near term. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of COVID-19 on the Company's ongoing and future operations, including potential negative impacts on Akero's employees, third-parties, manufacturers, supply chain and production as well as on global economies and financial markets; the success, cost, and timing of the Company's product candidate development activities and planned clinical trials; the Company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the Company's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero's Annual Report on Form 10-K for the year ended Akero Therapeutics, Inc. View the basic AKRO option chain and compare options of Akero Therapeutics, Inc. on Yahoo Finance. Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes. Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed … Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's …
Watts on why the ‘race issue’ is costing Republicans Black votersLender announces 30-year home loan under 2%, even as mortgage rates riseClaflin University President on closing the endowment gap and how HBCUs have been handling COVID-19China's retail sales unexpectedly fall as consumer caution prevailsFacebook Bracing for an Election Night Without ResultsJoe Biden's tax policy puts these 16 consumer company stocks at risk: Goldman SachsCoronavirus update: U.S. cases trending down as flu and back-to-school seasons loomApple stock is still undervalued and the new 'bundles' show why: analystHow Barstool’s deal with Penn National could boost the gaming company’s stock priceWheaton Precious Metals (WPM) Q2 2020 Earnings Call TranscriptCramer Says These 10 Stocks Need To Follow Tesla, Apple's Lead And Split‘It's going to trigger him’: Trump insiders say Kamala Harris is the president’s nightmare, but they have a warning for Democrats Breakdown.
These results have increased our confidence in EFX's potential to become a foundational NASH monotherapy," said Clinically meaningful improvements in glycemic control, weight loss and lipoproteins were also observed in the main BALANCED study. Logo (PRNewsfoto/Akero Therapeutics, Inc.)Cash and cash equivalents and short-term marketable securitiesJ.C. Share your opinion and gain insight from other stock traders and investors. Learn more. Find the latest Akero Therapeutics, Inc. (AKRO) stock discussion in Yahoo Finance's forum. Currency in USD
Get the detailed quarterly/annual income statement for Akero Therapeutics, Inc. (AKRO).
We observed improvements in histological parameters of NASH after only 16 weeks of treatment, the magnitude of which is among the highest observed to date across the NASH field, despite other compounds having been evaluated for 24 to 78 weeks. NASH is closely linked to the obesity and diabetes epidemics seen around the world.
"During the second quarter of 2020, we reported the first histological results for our FGF21 analog, efruxifermin (EFX), formerly AKR-001. Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed …
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding the Company's business plans and objectives, including future plans or expectations for EFX, upcoming milestones, and therapeutic effects of EFX; Akero's Phase 2a BALANCED study, including its results and expected timing to report the analysis of efficacy and safety data; expectations regarding the design, implementation, timing, and success of its current and planned clinical trials for EFX; expectations regarding successful scale-up of drug substance manufacturing and release of new drug product for use in clinical trials; expectations regarding the Company's use of capital, expenses and other future financial results; statements regarding the timing of the FDA's review of the registrational development plan; the Company's planned efforts to prepare for commercialization of EFX, if approved and the potential impact of COVID-19 on strategy, future operations, enrollment and clinical trials.
Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.